The shares of GlaxoSmithKline ($GSK) cheered on Monday after the British pharmaceutical giant announced that its chief ...
TipRanks on MSN
GSK Announces Total Voting Rights and Capital Update
GSK plc has announced its total voting rights and capital as of September 30, 2025. The company’s issued share capital consists of over 4.3 billion ordinary shares, with a total of approximately 4.07 ...
GSK commits $30 billion investment in U.S. R&D and manufacturing during Trump’s UK state visit, strengthening its focus on ...
GSK named Luke Miels to succeed Emma Walmsley as the British drugmaker’s CEO. - chris j ratcliffe/Reuters GSK said Emma ...
Dame Emma Walmsley will step down as GSK’s chief executive at the end of the year, concluding nine years at the helm of Britain’s second-largest pharmaceuticals company.
14don MSN
GSK adding a biologics factory in Upper Merion as part of a $1.2 billion investment in the U.S.
The new projects, including AI efforts in Pennsylvania and three other states, are part of the British firm's pledge to ...
GlaxoSmithKline (GSK) and Eli Lilly are making major U.S. manufacturing commitments as global pharmaceutical companies expand ...
It has been about a month since the last earnings report for GSK (GSK). Shares have added about 10.3% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...
In addition to Kepler Capital , GlaxoSmithKline also received a Hold from Deutsche Bank ‘s Emmanuel Papadakis in a report issued on August 27. However, on August 18, TR | OpenAI – 4o reiterated a Buy ...
Citi analyst Peter Verdult maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £19.00. The company’s shares closed yesterday at p1,458.25. According to ...
UPDATE: GSK denies it is remotely monitoring its sales reps' laptops. See comment below. Some GlaxoSmithKline (GSK) drug sales reps are freaking out over their employer's move to install Fiberlink 360 ...
GlaxoSmithKline (GSK) will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology, and inflammation (RI&I) as well as oncology, through a collaboration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results